Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

Last updated: October 31, 2016
Sponsor: Hospital de Clinicas de Porto Alegre
Overall Status: Active - Recruiting

Phase

4

Condition

Attention Deficit/hyperactivity Disorder (Adhd - Adults)

Williams Syndrome

Treatment

N/A

Clinical Study ID

NCT02951754
100358
  • Ages > 18
  • All Genders

Study Summary

Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • White Brazilian of European descent

  • Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, FourthEdition, (DSM-IV) diagnostic criteria for ADHD

  • Eligibility to immediate-release MPH (IR-MPH) treatment

Exclusion

Exclusion Criteria:

  • Contraindication for IR-MPH use

  • Current stimulant treatment

  • Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)

  • Current or past history of psychosis

  • Estimated intelligence quotient score lower than 70

Study Design

Total Participants: 600
Study Start date:
February 01, 2002
Estimated Completion Date:
December 31, 2032

Study Description

Methylphenidate (MPH) is the most prescribed psychostimulant for children and adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Meta-analyses and systematic reviews have shown that MPH is safe and efficacious in attenuating the core symptoms of ADHD, promoting overall clinical improvement. However, many patients still do not show an appropriate clinical response to the MPH treatment and there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. Therefore, it is essential to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.

Connect with a study center

  • Program on Attention-Deficit/Hyperactivity Disorder (PRODAH); Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul 90035-903
    Brazil

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.